Getting Serious about High U.S. Drug Prices

The U.S. pharma industry is under attack by executive order, with the latest salvo designed to ensure the Medicare Part B program pays the same price for drugs as similarly developed nations pay. That order joins others issued this summer, all aimed at high U.S. drug prices. These orders – all variants of previous orders and […]

Read More

Opening the Course to Price Transparency by Closing the Safe Harbor on Part D Drug Rebates

The Centers for Medicare & Medicaid Services (CMS) is about to publish a proposed rule that – according to the Health and Human Services Department (HHS) – would lower prescription drug prices and out-of-pocket costs for patients and increase pricing transparency. The HHS proposal would eliminate a safe harbor for prescription drug rebates that drug […]

Read More